| 恩替卡韦在HBeAg阳性的慢性乙型肝炎患者中的长期疗效及安全性 |
| 投稿时间：2011-01-05 修订日期：2011-01-24 点此下载全文 |
| 引用本文：施丽妮.恩替卡韦在HBeAg阳性的慢性乙型肝炎患者中的长期疗效及安全性[J].医学研究杂志,2011,40(9):146-148 |
| DOI：
|
| 摘要点击次数: 1071 |
| 全文下载次数: 1249 |
|
|
| 中文摘要:目的评价恩替卡韦在HBeAg阳性的慢性乙型肝炎患者中的长期抗病毒作用及安全性。方法共63例HBeAg阳性的慢乙肝患者入选。患者接受恩替卡韦0.5mg/d每日1次口服抗病毒治疗96周。入选患者每3个月随访1次，定期复查肝功能及HBV DNA，并记录不良发应事件。随防至治疗结束。结果治疗结束后有74%的患者达到HBV DNA阴转，有79%的患者达到谷丙转氨酶复常，有24%的患者达到HBeAg血清转换，没有患者获得HBs抗原血清转换或阴转，有1例患者出现病毒学突破。有52%例患者出现不良反应，最常见的是上腹部不适、头痛及咳嗽。没有患者因为无法耐受的不良反应而退出研究。结论恩替卡韦在治疗HBeAg阳性慢乙肝中具有持续抑制病毒复制的作用及较好的安全性，但需要更大样本的试验来证实。 |
| 中文关键词:恩替卡韦 HBeAg阳性 慢性乙型肝炎 |
| |
| Long-term Efficacy and Safety of Entecavir in the Treatment of HBeAg-positive Chronic Hepatitis B |
|
|
| Abstract:ObjectiveTo evaluate the long-term efficacy and safety of entecavir for the treatment of HBeAg-positive chronic hepatitis B (CHB).MethodsAll 63 consecutive patients with HBeAg-positive CHB were enrolled and orally given entecavir 0.5mg daily for 96 weeks.Follow-up were conducted every 3 months,including ALT and HBV DNA level and reports of adverse events.Results 74% patients achieved serum negativity of HBV DNA,79 percent with ALT normalization and 24 percent with HBeAg sero-conversion.However,none acquired HBeAg loss or sero-conversion.Virologic breakthrough was observed in one patient.Adverse events occurred in 52 percent patients,the most common of which were epigastric discomfort,headache and cough.However,there was no withdrawal from the study due to reported adverse events.ConclusionEntecavir provides sustained HBV DNA suppression and is well-tolerated in HBeAg-positive CHB patients.However,these should be further examined in larger studies. |
| keywords:Entecavir Hepatitis Be antigen positive Chronic hepatitis B |
| 查看全文 查看/发表评论 下载PDF阅读器 |
